摘要
目的探讨伊托必利联合铝碳酸镁治疗胆汁反流性胃炎的临床疗效,并分析疾病形成的影响因素。方法以2010年4月-2013年4月间来院治疗胆汁反流性胃炎的128例患者为研究对象,将其随机分入观察组和对照组进行治疗,每组均有64例患者,组间无显著性差异(p〉0.05)。其中观察组患者采用伊托必利(50 mg×20片/盒)联合铝碳酸镁(0.5 g×20片/盒)治疗,对照组患者采用多潘立酮(10 mg×30片/盒)联合铝碳酸镁(0.5 g×20片/盒)治疗。治疗结束后,统计对比两组患者在临床疗效、胃镜检查结果、呕吐胆汁及腹痛症状消失时间之间的差异。结果观察组患者治疗有效率较对照组高,差异有统计学意义(p〈0.05),治疗后,观察组中胃黏膜有充血、糜烂、胆汁染色症状的患者所占比例明显低于对照组,差异有统计学意义(p〈0.05);观察组患者呕吐胆汁和腹痛症状消失早于对照组患者,差异具有统计学意义(p〈0.05)。结论伊托必利联合铝碳酸镁治疗胆汁反流性胃炎的临床疗效好,有效率高,症状改善明显。
Objective To analysis the effect of different drug plan in the treatment of bile reflux gastritis and to discuss the related influencing factors. Method 128 patients with bile reflux gastritis were divided into objective group and the control group. The hydrotalcite was used in all the patients. The itopride was used in the objective group, and the domperidone was used in the con- trol group. The difference of clinical effect, clinical symptoms and the characteristics of gastric juice between the two groups were com- pared. Result The clinical effect of the objective group was higher. The clinical symptoms of the objective group was less. The char- acteristics of gastric juice in the objective group was better. Conclusion It would get a satisfactory effect to use itopride in the treat- ment of bile reflux gastritis, with better clinical effect and less clinical symptoms.
出处
《现代医院》
2014年第10期29-31,共3页
Modern Hospitals
基金
国家自然科学基金资助项目(编号:81060205)
关键词
胆汁反流性胃炎
影响因素
伊托必利
Bile reflux gastritis, Influencing factors, Itopride.